It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Integrated Drug Discovery
We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.
At Sygnature Discovery our teams work across the drug discovery process, from target identification through to candidate selection and pre-clinical development. With more than 700 experts from over 50 countries, and no internal drug pipeline, our sole focus is your success.
In drug discovery, collaboration is key, not only to the quality of the output, but to the speed of delivery.
At Sygnature Discovery, we don’t operate in silos. Our multidisciplinary teams work side by side in shared offices and laboratories, enabling real-time collaboration, transparency, and faster decision-making. Physical proximity eliminates delays, accelerates DMTA cycles, and aligns disciplines, moving ideas quickly from data to decision. Our agile, integrated approach shortens feedback loops, enhances problem-solving and enables us to deliver high-quality candidates with speed and confidence.
Our Offering
We combine new talent and experienced pharmaceutical industry experts from around the world, with advanced technologies, to deliver excellence across every stage of discovery. We have 3 fully integrated drug discovery hubs in the UK and North America.
Target Identification & Validation
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
We tailor every integrated drug discovery program to your needs.
Our globally recruited scientists work within a transparent, collaborative framework supported by advanced informatics and a co-located infrastructure. Each program is led by a highly qualified and dedicated project leader with relevant drug discovery experience, ensuring strategic alignment and scientific rigor from start to finish. We deliver robust, decision-ready data, even for the most complex projects. Our teams are committed to working closely with you, sharing knowledge, solving problems, and driving progress together.
Drug discovery is evolving, and so are the challenges. As global health demands rise, the need for smarter, faster, and more connected science has never been greater. Yet too often, progress is slowed by disconnection between disciplines and data.
At Sygnature Discovery, our aim is to reshape how drug discovery is delivered. Through flexible services and integrated expertise, we enable innovation at every stage. With AI and automation embedded across our workflows, we help you move faster and make confident decisions, delivering high quality results with integrity.
Whether we’re supporting you through the entire process or just a part of it, our goal isn’t simply to move you to the next stage, it’s to lay the foundations for a successfully marketed drug.
Since 2011, Sygnature Discovery has delivered over 60 novel pre-clinical and 35+ clinical compounds, with our scientists named on over 200 patents. Our therapeutic areas of expertise span oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.
What sets Sygnature apart is our co-located, multidisciplinary setup, where chemists, biologists, DMPK experts, and in vivo pharmacologists work side by side in shared lab spaces. This physical proximity fosters real-time collaboration, transparency, and faster decision-making, eliminating delays. It enables tighter alignment across disciplines, accelerates DMTA cycles, and ensures that every project is focused on a collective drive towards the identification of a strong candidate.
It has been a pleasure to work with the Sygnature team on our best-in-class inhibitor project. From project start, the multidisciplinary team at Sygnature functioned as an extension of our in-house team, providing additional expertise across the drug discovery process; particularly in protein sciences, computational and synthetic chemistry and in vivo biology.
They responded fearlessly to our ambitious timelines and collaborated closely to allow us to achieve preclinical candidate compound nomination within a really impressive timeframe. I wouldn’t hesitate to work with the Sygnature team again.
Helen Harrison
Director of Discovery Biology, STORM Therapeutics
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Accelerating a best in class DHX9 inhibitor ahead of industry timelines.
See how STORM Therapeutics and Sygnature Discovery moved from lead to pre candidate nomination in
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
